Head to Head Review: Xenetic Biosciences (NASDAQ:XBIO) versus Allarity Therapeutics (NASDAQ:ALLR)
by Kim Johansen · The Markets DailyXenetic Biosciences (NASDAQ:XBIO – Get Free Report) and Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.
Profitability
This table compares Xenetic Biosciences and Allarity Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xenetic Biosciences | -75.90% | -40.62% | -34.97% |
| Allarity Therapeutics | N/A | -152.77% | -46.50% |
Institutional & Insider Ownership
15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Xenetic Biosciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for Xenetic Biosciences and Allarity Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xenetic Biosciences | 1 | 0 | 0 | 0 | 1.00 |
| Allarity Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Allarity Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 885.58%. Given Allarity Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Xenetic Biosciences.
Valuation and Earnings
This table compares Xenetic Biosciences and Allarity Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xenetic Biosciences | $2.98 million | 1.72 | -$2.68 million | ($1.16) | -1.93 |
| Allarity Therapeutics | $320,000.00 | 51.71 | -$11.23 million | ($0.78) | -1.33 |
Xenetic Biosciences has higher revenue and earnings than Allarity Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
About Allarity Therapeutics
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.